USPTO Patent Applications - Peptides (C07K)

Cell-Free Vascular Grafts and Graft Materials for Cellular Recruitment

USPTO published patent application US20260097149A1 for cell-free vascular graft materials incorporating bispecific binding partners with luminal and cellular binding domains for cellular recruitment. The application, filed June 26, 2023 under Application No. 18880781, covers fusion peptides with heparin and monocyte binding domains, methods of making the grafts, and methods of use including A-TEV technology.

Method for Treating Neurodegenerative Diseases with Polymer-Flavonoid Conjugates

The USPTO published patent application US20260097130A1 for a method of treating neurodegenerative diseases using polymer-flavonoid conjugates. Inventors Chun-Ting Cheng, Kuo-Liang Hou, and Pauline Ying Lau claim compositions that enable therapeutic materials to cross the blood-brain barrier. The application covers treatment of Alzheimer's disease, Parkinson's disease, Lewy body dementia, and Huntington's disease using the disclosed nanocomplex formulations.

Implantable Device for Administering a Therapeutic Agent

USPTO published patent application US20260096984A1 filed by inventors Harsh Patel and Jeffrey Haley on October 3, 2025. The application covers an implantable device for delivering therapeutic agents, featuring a core polymer matrix with hydrophobic poly ortho ester (POE) polymer having a glass transition temperature between -20°C and 40°C. The device is designed for controlled therapeutic agent release in vivo.

Solanum Lycopersicum Plants Having Improved Tobamovirus Resistance

The USPTO published patent application US20260096533A1 granting protection for hybrid Solanum lycopersicum tomato plants containing the Rug-1 resistance gene that confers Tomato Brown Rugose Fruit Virus (ToBRFV) tolerance/resistance. The patent covers the plant, seeds, fruits, plant parts, and methods for identifying, selecting, and producing ToBRFV-resistant tomato plants using the specified genetic marker.

Antibody-Drug Conjugate Targeting GRP94 for Cancer Treatment

The USPTO published patent application US20260097129A1 for an antibody-drug conjugate comprising a drug and an antibody specifically binding to GRP94 (glucose-regulated protein 94) or an antigen-binding fragment thereof. The invention includes a pharmaceutical composition for treating cancer, leveraging strong internalization activity against GRP94-overexpressed carcinomas. The conjugate effectively inhibits growth of cetuximab-resistant colorectal cancer cell lines including HT29, HCT116, HCT8, and LoVo cells.

Dosages of Emactuzumab for TGCT Treatment, SYNOX Therapeutics

The USPTO published patent application US20260098087A1 by SYNOX Therapeutics UK Limited covering dosage regimens of emactuzumab, an anti-CSF-1R antibody, for treating tenosynovial giant cell tumour (TGCT). The application, filed October 20, 2025, describes treatment regimes and methods using the colony stimulating factor-1 receptor-binding antibody. The application is now publicly available as part of the standard patent examination process.

IL-8 Signal Inhibitor Composition for Prophylaxis or Treatment of IL-8 Related Diseases

USPTO published patent application US20260098086A1 on April 9, 2026, covering compositions for prophylaxis or treatment of IL-8 related diseases using IL-8 signal inhibitors and anti-IL-8 antibodies. The application was filed December 5, 2025, by inventors Ayako KAKIUCHI, Atsuhiko Kato, Shuji Hayashi, Izumi Yanagisawa, Ryo Konno, Sachiho Netsu, and Tadashi Sankai. The published application contains CPC classifications related to antibodies and therapeutic compositions.

Multimeric T-Cell Modulatory Polypeptides and Methods of Use Thereof

The USPTO has published patent application US20260097127A1 for multimeric T-cell modulatory polypeptides comprising immunomodulatory polypeptides and epitope-presenting Wilms tumor peptides. The application, filed October 6, 2025, names Saso Cemerski, Rodolfo J. Chaparro, Ronald D. Seidel III, and John F. Ross as inventors. The published application covers methods for modulating T-cell activity and immune responses using the disclosed polypeptides.

AMD Treatment with VEGF Antagonist Dosing at 8 or 12 Weeks

USPTO published patent application US20260098085A1 titled 'Methods for Treating Age-Related Macular Degeneration.' The application covers methods for reducing treatment burden for patients with intraocular neovascular disorders by administering VEGF antagonists on 8-week and/or 12-week dosing schedules. Inventors include Margarita Gekkieva, Peter Sallstig, Werner Schmidt, James Warburton, and Andreas Weichselberger. The application was filed on June 25, 2025.

Mammalian Cell SHMT2 Reduction for Protein Production

USPTO published patent application US20260098081A1 disclosing isolated mammalian cells with reduced or eliminated SHMT2 expression and methods for using such cells in recombinant protein production. The application names Samuel Peters, James Ravellette, David Razafsky, Jason A. Gustin, and Trissa Borgschulte as inventors. Filing date was September 29, 2023, under application number 19112697.

Protein Purification Using Chemically Activated Carbon at 0.1-15 wt%

USPTO published patent application US20260098056A1 for a method of purifying proteins from fermentation-derived solutions using chemically activated carbon. The method involves contacting the solution with 0.1-15 wt% activated carbon at pH 4-12 and temperature 2-60°C. Inventors: Sebastian Schoof, Thomas Kaeding, Gabriele Iffland. Application filed October 6, 2025.

Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis US20260098088A1

USPTO published patent application US20260098088A1 assigned to Disc Medicine, Inc. The application covers anti-hemojuvelin (HJV) antibodies and methods for treating myelofibrosis and associated conditions. Inventors include Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, and Jennifer M. Perez. CPC classifications include C07K 16/28 and related antibody technology classes.

Anti-CGRP Monoclonal Antibodies for Treating Nausea and Vomiting Including CINV

The USPTO published patent application US20260098082A1 for methods using anti-Calcitonin gene related peptide (CGRP) monoclonal antibodies to treat nausea and vomiting, including chemotherapy-induced nausea and vomiting (CINV). The application, filed September 13, 2023, claims methods of preventing and counteracting CINV by targeting CGRP, a neuropeptide associated with emetic responses to chemotherapy and other triggers.

Cμ4 Region for Multi-Specific Antibody Chain Pairing

USPTO published patent application US20260098094A1 assigned to DNA Twopointo, Inc. covering multi-specific antibodies with IgM Cμ4 region pairing domains for correct heavy and light chain pairing. The invention promotes correct chain combinations and disfavors incorrect pairings in bispecific antibodies. The application was filed November 21, 2025.

HIV/HBV Treatment Using CD8-Targeting Fusion Proteins

USPTO published patent application US20260098090A1 on April 9, 2026, disclosing fusion proteins for treating chronic viral infections including HIV and HBV. The application describes methods using CD8-targeting fusion proteins comprising antibodies specific to CD8b or CD8ab antigens combined with cytokines, chemokines, or growth factors. Inventors are Kelly Dare Moynihan, Yik Andy Yeung, and Ivana Djuretic, with filing date September 28, 2023.

CD7 Antibody Antagonists for Therapeutic Applications

USPTO published patent application US20260098089A1 titled 'CD7 Antibody Antagonists for Therapeutic Applications' filed September 8, 2025 by inventors E-Chiang Lee, Gwenoline Borhis, Cassandra Van Krinks, Lucy Hepburn, Luke Bayliss, and Miha Kosmac. The application covers Cluster of Differentiation 7 (CD7) antibody antagonists and fragments for therapeutic uses, including methods, uses, and combinations. Patent applications establish priority dates and filing status but do not yet grant enforceable intellectual property rights.

Modified Protein Scaffold Patent by Evolveritas

The USPTO published patent application US20260098080A1 for a modified protein scaffold comprising amino acid sequence SEQ ID NO: 115 with specific amino acid modifications in defined positions. The application was filed by Evolveritas Biotechnológiai Korlátolt Felelősségű Társaság, a Hungarian biotechnology company, with eight named inventors. The claimed protein scaffold includes segment formula Ih-mod GX1CX1VX2X3X4X5 and is intended for pharmaceutical preparations, kits, and screening procedures.

High-Purity Recombinant Human Albumin Preparation Method

Tonghua Anrate Biopharmaceutical Co., Ltd. has filed USPTO Patent Application US20260098079A1 for a method of preparing high-purity recombinant human albumin using medium-long-chain fatty acid ligands and ion exchange chromatography. The application discloses a process where oleic acid, myristic acid, sodium palmitate, and sodium stearate are combined with recombinant human albumin in defined molar ratios with poloxamer to achieve high stability and purity through sequential anion and/or cation chromatography to remove truncated and modified albumins.

Protein Crystallization Method, Multiple Protein Feeds

Protein Crystallization Method, Multiple Protein Feeds

Advagene Biopharma Patent for Asthma Treatment Using Detoxified E. coli Labile Toxin

USPTO published patent application US20260098065A1 assigned to Advagene Biopharma Co., Ltd. covering methods for treating eosinophil-driven inflammation including severe asthma using a composition for mucosal administration comprising detoxified Escherichia coli labile toxin.

LANMODULIN ORTHOLOGS WITH IMPROVED RARE EARTH SEPARATION PERFORMANCE

USPTO published patent application US20260098064A1 for lanmodulin orthologs (proteins) designed to bind rare earth metals with enhanced REE/REE selectivity. The application covers proteins with four EF hand motifs, methods of using the proteins, and devices/kits containing them. The invention has applications in rare earth element separation and processing.

HPV Vaccine Peptide Constructs with Ligand-Inducible Gene Switch Systems

The USPTO published patent application US20260098063A1 titled 'Human Papillomavirus Vaccines and Uses of the Same.' The application covers engineered HPV molecular vaccine constructs incorporating ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as cytokines, in host cells. The application was filed on July 7, 2025, by inventors including Douglas E. Brough and Cheryl G. Bolinger. Patent applications are published for informational purposes and do not grant enforceable rights until issued as a patent after examination.

Lipid Particles Comprising Variant Paramyxovirus Attachment Glycoproteins

USPTO published patent application US20260098062A1 assigned to Sana Biotechnology, Inc. covering lipid particles comprising variant Paramyxovirus attachment glycoproteins with reduced glycosylation and methods for their production and use. The application (originally filed September 21, 2023) covers viral-based particles with modified G/H proteins and their therapeutic applications.

EphA2-binding Peptide and Composition Patent Application

The USPTO published patent application US20260098061A1 for an EphA2-binding peptide and composition comprising such peptides. The application, filed on September 28, 2023, lists 13 inventors including Takanori Aoki and others. The patent covers peptides that bind to the Eph receptor A2 (EphA2) and compositions containing such peptides, with CPC classifications C07K 7/64 and A61K 47/64.

Macrocyclic CFTR Modulators for Cystic Fibrosis

USPTO published patent application US20260098060A1 for macrocyclic CFTR modulators for treating cystic fibrosis. The application covers compounds of Formula (I), their preparation, pharmaceutical salts, and uses as CFTR modulators or in combination with CFTR potentiators/correctors. Inventors include Martin Bolli, Christine Brotschi, John Gatfield, and others. The application was filed on September 14, 2023.

Peptide Compositions Targeting β-Catenin for Treatment of Endometriosis

USPTO published patent application US20260098059A1 for peptide compositions targeting β-catenin for treatment of endometriosis. The application covers peptides that bind β-catenin and prevent nuclear translocation, modulating the canonical Wnt pathway. Filed October 10, 2025 under Application No. 19355926. Patent rights are not yet granted; applicants seeking to develop similar therapies should review the published claims for freedom-to-operate considerations.

Ovarian Cancer Diagnostic Marker, Urteste S.A

Ovarian Cancer Diagnostic Marker, Urteste S.A

CRISPR Methods for Treating Microbial Infections - SNIPR Biome

SNIPR Biome ApS filed USPTO patent application US20260098260A1 covering CRISPR-based methods for treating microbial infections including sepsis, septicemia, SIRS, and septic shock. The application also covers controlling microbiologically influenced corrosion and biofouling in industrial or domestic systems using CRISPR technology. Inventors include Morten Sommer, Virginia Martinez, Eric van der Helm, Jakob Krause Haaber, Ana de Santiago Torio, Christian Grøndahl, and Jasper Clube.

Compositions and Methods for Identification of VHH Antibodies That Bind a Target Antigen

The USPTO published patent application US20260098255A1 for Broad Institute's VHH antibody identification methods. The application covers compositions and methods for identifying VHH antibodies that bind target antigens. The application (No. 19415305) was filed December 10, 2025, and published April 9, 2026.

Anti-SIRPalpha Antibody for Tumor Treatment

USPTO published patent application US20260098102A1 by National University Corporation Kobe University on April 9, 2026. The application discloses an anti-SIRPα monoclonal antibody that binds human SIRPα to inhibit the SIRPα/CD47 interaction for use as an anti-tumor agent. The invention is classified under C07K 16/28 and related peptide technology categories.

Anti-IL-36R Monoclonal Antibody and Use Thereof for Inflammatory Disease Treatment

USPTO published patent application US20260098101A1 from QYUNS THERAPEUTICS CO., LTD. covering an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody for inflammatory disease treatment. The application was filed on December 4, 2025. The antibody comprises six complementarity determining regions with amino acid sequences specified in the filing, and the applicant claims superior neutralizing activity compared to Spesolimab at the cellular level.

IL-4R and TSLP Inhibitors, Inflammatory Treatment Patent Application

USPTO published patent application US20260098100A1 covering antigen binding moieties that inhibit IL-4R and TSLP pathways for inflammatory disease treatment. The application names Miguel A. Sanjuan, Sheila Gujrathi, and Ryan P. Sullivan as inventors and was filed November 10, 2025. The disclosed invention blocks IL4-IL-4R and TSLP-TSLPR interactions, targeting the same pathways addressed by approved drugs Dupilumab and Tezepelumab.

Anti-sIL7R Antibody Therapy for Treating Autoimmune Diseases

The USPTO published patent application US20260098099A1 assigned to the Board of Regents of the University of Texas System, covering methods and compositions for anti-soluble interleukin-7 receptor (sIL7R) antibodies for treating autoimmune diseases including multiple sclerosis, lupus nephritis, type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. The application was filed on August 10, 2025.

Polygon Therapeutics Anti-CD8 Antibodies for Immunotherapy

Polygon Therapeutics Anti-CD8 Antibodies for Immunotherapy

Methods for Rule-based Genome Design

USPTO published patent application US20260100251A1 for computer-implemented methods of rule-based genome design. The application covers systems receiving known genome data and allele lists, generating alternative gene sequences, and scoring each sequence using a weighted combination of multiple rules, constraints, or parameters. Inventors include George M. Church and Nili Ostrov.

TACI Antibody and Use Thereof for Detecting Free Drug Levels

The USPTO published patent application US20260098866A1 covering a human TACI (B lymphocyte stimulator receptor) antibody with high specificity and affinity, along with methods for detecting free TACI or TACI-Fc fusion protein drug levels in patients. The invention enables monitoring of drug absorption and therapeutic efficacy in patients with autoimmune diseases.

NAVROGEN Fc-Engineered Monoclonal Antibodies Targeting ICAM-1/CD54 for Cancer Treatment

USPTO published patent application US20260098858A1 for NAVROGEN, INC. covering Fc-engineered monoclonal antibodies with CH3 region modifications designed to reduce ICAM-1/CD54 binding, improving immune-effector activity and antibody drug conjugate killing for cancer and inflammatory disease treatment.

Surface-Modified Viral Particles and Modular Viral Particles Patent Application

USPTO published patent application US20260098280A1 for surface-modified viral particles and modular viral particles (anellovectors and anelloVLPs) filed December 8, 2025. The application names five inventors including Simon Delagrave, Kurt Adam Swanson, and Noah Robert Cohen. CPC classifications include C12N 15/86 and C07K 14/005.

Composition Improves Salt Tolerance in Plants

Composition Improves Salt Tolerance in Plants

Macrocycle and Hydrophobic Particle Method for Removing Polymers from Protein Solutions

USPTO published patent application US20260098055A1 for a method of removing free polymers from solutions containing hydrophobic proteins using macrocycles and/or hydrophobic particles. The application (CPC C07K 1/145) was filed September 7, 2023, with inventors including Barbara Maertens and colleagues. This pre-grant publication does not confer any enforceable rights.

Methods for Constructing Conjugates Using Ortho-Phthalaldehyde

USPTO published Patent Application US20260098054A1 disclosing methods for constructing conjugates using ortho-phthalaldehyde. The method involves reacting an amine-containing component with a thiol-containing component in comparable mole ratios to generate a conjugate bearing a substituted or unsubstituted 1-thio-isoindole structure. Inventors are Xuechen LI and Hey Pui CHEUNG. The application was filed on August 22, 2023.

METHOD FOR TREATING MEMBRANOUS NEPHROPATHY WITH TACI-FC FUSION PROTEIN

USPTO published patent application US20260098077A1 for a method of treating membranous nephropathy using TACI-Fc fusion protein. The application, filed September 28, 2023, discloses dosage schemes, administration intervals, and clinical efficacy data showing good safety profiles in patients.

Modified LGICs with Altered Ligand Binding, Ion Pore Domains

USPTO published patent application US20260098076A1 for modified ligand-gated ion channels (LGICs) with altered ligand binding domains and ion pore domains. The invention covers exogenous LGIC ligands, methods for modulating ion transport and cell excitability in mammals, and methods for treating channelopathies. The application was filed on February 24, 2025.

CAR TCR Cell Therapy Patent Improves Cytokine Signaling

USPTO published patent application US20260098074A1 by inventors Ruth E. Winter and Saikat Banerjee for CAR and/or TCR cell therapy improving cytokine signaling. The patent covers methods for enhancing immune cell function through improved cytokine signaling pathways in cell therapy applications. The application was filed on 2025-07-15.

Washington University Patents UTI Treatment Using Hemolysin Inhibitor

The USPTO published Washington University's patent application (US20260098073A1) for compositions and methods treating urinary tract infection and sepsis using alpha-hemolysin (HlyA) inhibiting agents. The technology includes soluble LDLR-Fc fusion proteins, clathrin-mediated endocytosis inhibitors, and anti-LDLR antibodies targeting E. coli hemolysin. This grants Washington University exclusive IP rights over these therapeutic compositions.

Methods of Stimulating Appetite Using Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs

The USPTO published patent application US20260098072A1 by inventor Russell Potterfield on April 9, 2026, covering methods of increasing body weight and stimulating appetite using non-naturally occurring melanocortin receptor antagonist analogs. The application, filed April 18, 2025, relates to pharmaceutical compositions administered via parenteral routes such as subcutaneous injection for subjects requiring appetite stimulation and weight gain.

GLP-1 Analog for Treatment of GLP-1 Related Diseases

USPTO published patent application US20260098071A1 for a novel human GLP-1 analog invented by Tao Sun. The disclosed analog demonstrates improved efficacy compared to natural GLP-1 sequence in treating obesity, type 2 diabetes mellitus, fatty liver, and mood disorders including anxiety and depression. The application was filed on December 4, 2024, under application number 18968327.

SMAGP Fusion Molecules Modulate Leukocyte Activity

USPTO published patent application US20260098070A1 disclosing fusion molecules comprising a SMAGP extracellular domain designed to modulate leukocyte activity. The application covers polynucleotides, vectors, and host cells encoding these molecules along with methods of making and using them. Inventors include Loise M. Francisco-Anderson, Sandeep Kumar, Sarah Elizabeth Carden, Christophe Quéva, and Nenad Grmusa, with filing date July 7, 2025.

Recombinant Lubricin Patent - Schmidt and Jay Inventors

USPTO published patent application US20260098069A1 for recombinant isoforms of human-like lubricin (PRG4 glycoprotein) invented by Tannin A. Schmidt and Gregory D. Jay. The patent covers new lubricin isoforms with novel glycosylation patterns and methods for commercial-scale manufacturing using recombinant production methods.

DWORF Peptide SERCA Pump Activator Heart Failure Treatment

The USPTO published patent application US20260098067A1 by researchers at the University of Texas System covering the DWORF (Dwarf Open Reading Frame) peptide, a native SERCA pump activator for treating heart failure and disorders characterized by cytosolic calcium overload. The application claims compositions and methods using this positively inotropic and lusitropic therapeutic agent.